NVCR
NovoCure Ltd.
NASDAQ · Healthcare · Medical - Instruments & Supplies · JE
$16.69
−0.18%Sep 9, 2026, 11:05 UTC
Timothy Scannell retired as a Director of NovoCure Ltd, effective September 2, 2026.
Sep 1, 2026, 11:54 UTC
Oncology company Novocure disclosed a cybersecurity incident involving unauthorized access to its information systems in mid-August, which exposed internal records of more than 1,400 U.S. patients.
Source:Jul 23, 2026, 11:00 UTC
Novocure reported financial results for the second quarter ended June 30, 2026, with record net revenues and active patients on therapy.
Source:Jun 30, 2026, 11:00 UTC
Novocure received CE Mark for Optune Pax for the treatment of locally advanced pancreatic cancer.
Source:Jun 18, 2026, 11:08 UTC
Novocure's cancer treatment for newly diagnosed brain tumors failed to meet the main goal of a late-stage study.
Source:Jun 5, 2026, 00:00 UTC
NovoCure Ltd elected Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, and Frank Leonard as directors, effective June 3, 2026.